Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

K. Suzuki



Author of

  • +

    P1.20 - Poster Session 1 - Early Detection and Screening (ID 172)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Imaging, Staging & Screening
    • Presentations: 1
    • +

      P1.20-011 - Retrospective Study of Lung Cancer Screening. (ID 3372)

      09:30 - 09:30  |  Author(s): K. Suzuki

      • Abstract

      Background
      The lung cancer screening in Japan is only chest radiography now. But in 2011, the national lung screening trial research team was reported reduced lung-cancer mortality with low-dose computed tomographic screening. We studied lung cancer patients about a difference of a screening type, for example radiography and computed tomography.

      Methods
      From January 2008 through May 2013, we performed the operation of 1344 lung cancer patients. In those patients, 1018 patients were proved the type of screening.

      Results

      symptom radiography CT
      pt 146 340 378
      age 64±1 64±0.7 67±0.5
      cStage IA 50 199 296
      IB 22 66 42
      IIA 18 25 6
      IIB 15 13 8
      IIIA 25 21 12
      IIIB 6 4 2
      IV 7 3 1
      pStage IA 35 155 259
      IB 18 57 53
      IIA 12 31 13
      IIB 16 23 11
      IIIA 41 50 30
      IIIB 6 4 1
      IV 12 7 4
      The number of patients by symptom, radiography and computed tomography are 146 (14%), 340 (33%) and 378 (37%), respectively. The rate of clinical stage I (789, 78%) are 72 (7%), 265 (26%), 338 (33%), respectively. The rate of pathological stage I (672, 66%) are 53 (5%), 212 (21%), 312 (31%), respectively. On the other hand, the rate of clinical III are 31 (3%), 25(2%), 14 (1%), respectively. The rate of pathological III are 47 (5%), 54 (5%), 31 (3%), respectively. The difference of between clinical stage I and screening type are 0.000, 0.813, and 0.000, respectively. The difference of between pathological stage I and screening are 0.000, 0.081, and 0.000, respectively.

      Conclusion
      In the group of symptom and radiography, there are a lot of advanced lung cancer patients, while in the group of computed tomography, we can detect a lot of early lung cancer patients. Computed tomography is better than the other screening about the detecting lung cancer. We should use a computed tomography in screening of lung cancer.

  • +

    P2.07 - Poster Session 2 - Surgery (ID 190)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Surgery
    • Presentations: 1
    • +

      P2.07-050 - Short term preoperative efficacy of tiotropium for patients with resectable lung cancer and chronic obstractive pulmonary disease: Preliminary results of one arm prospective study (ID 3472)

      09:30 - 09:30  |  Author(s): K. Suzuki

      • Abstract

      Background
      It was reported that in chronic obstructive pulmonary disease (COPD) patients, tiotropium improves lung function. However diagnosis of COPD is often made during evaluation of patients with lung cancer for surgical intervention and the efficacy of tiotropium for these patients is unclear. Thus a prospective study is needed to investigate it.

      Methods
      A prospective study was conducted on patients undergoing pulmonary resection for lung cancer with COPD (ratio of forced expiratory volume in 1 second (FEV~1~)/ forced vital capacity (FVC) less than 70%) between July 2011 and January 2012. Patients with a known history of asthma, chronic respiratory disease other than COPD were excluded. Primary endpoint was evaluating the incidence of postoperative complication. Secondary endpoints were improvement of pulmonary function tests after more than 1-week treatment using tiotropium preoperatively.

      Results
      Of 168 lung cancer patients for six months, 21 (12.5%) patients with COPD were enrolled. Pulmonary complications (prolonged air leak; 4 (19.0%), sputum retention; 2 (9.5%), hypoxia needing transient home oxygen therapy; 2 (9.5%)) were observed in seven (33.3%), although there was no critical complication such as acute respiratory failure and no side-effect related tiotropium. Treatment of tiotropium resulted in a significant improvement of FVC (pre-FVC 2.96±0.70 vs post-FVC 3.18±0.58; p=0.005) and FEV1 (pre-FEV~1~ 1.78±0.44 vs post FEV~1~ 1.91±0.18; p=0.0003), but there was no significant difference between pre-RV (residual volume) / TLC (total lung capacity)% and post-RV/TLC% ( 108.8±20.1 vs 102.4±16.1; p=0.237).

      Conclusion
      In this prospective study, we were safely able to use tiotropium without critical complication and it improved FVC and FEV~1~ in patients with COPD. But it did not improve RV/TLC% statistically and there remains doubt about efficacy of titropium. We thought that there is a problem of compliance in inhalation drug and need to reveal the population in which tiotropium was effective, and then we should perform a prospective randomized control trial.

  • +

    P2.09 - Poster Session 2 - Combined Modality (ID 213)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Combined Modality
    • Presentations: 1
    • +

      P2.09-016 - A feasibility study of neoadjuvant chemotherapy with cisplatin, pemetrexed and bevacizumab followed by surgery for nonsquamous non-small cell lung cancer (ID 2956)

      09:30 - 09:30  |  Author(s): K. Suzuki

      • Abstract

      Background
      Bevacizumab and pemetrexed/cisplatin improves the response and survival in patients with advanced or metastatic non-small cell lung cancer (NSCLC); however, the role of these medications in the setting of induction therapy for NSCLC is not well defined. The purpose of this study was to evaluate the feasibility of induction combination therapy with cisplatin, pemetrexed and bevacizumab followed by surgery in patients with clinical stage II/IIIA nonsquamous NSCLC.

      Methods
      Patients with clinical stage II/IIIA nonsquamous NSCLC were enrolled. The induction chemotherapy consisted of three cycles of cisplatin (75 mg/m[2]), pemetrexed (500 mg/m[2]) and bevacizumab (15 mg/kg) on Day 1, administered every 21 days. At least six weeks after the last administration of bevacizumab, the patients underwent surgical resection. The primary endpoint was the complete resection rate after the completion of three cycles of induction chemotherapy. The sample size was set at 30. The feasibility of the treatment was considered to be confirmed if the complete resection rate was 80% (24/30) or more.

      Results
      A total of six institutions in Japan participated in this trial. The study was initiated in June 2010, and patient enrollment was completed in November 2012. Thirty-one patients were recruited, 30 of which were eligible. The median age was 64 years (range: 54-71), and the male/female ratio was 17/13. The PS0/PS1 ratio was 29/1, the adenocarcinoma/large cell carcinoma ratio was 30/0 and the clinical stage IIA/IIB/IIIA ratio was 5/3/22. Grade 3 toxicities included neutropenia (7%), nausea (7%), appetite loss (13%), hypertension (23%) and pulmonary embolism (3%). There were no grade 4 events, and 27 (90%) patients completed three cycles at the full dose of chemotherapy. All but one patient exhibited radiologic tumor reduction based on the RECIST criteria. The objective responses to chemotherapy was CR in 0% of the patients, PR in 37%, SD in 50% and PD in 10% (due to new lesions). The disease control rate (CR+PR+SD) was 87%. Five patients dropped out from the study before surgery due to the patient’s decision in one patient, adverse events in three and disease progression in one. The complete resection rate after the completion of three cycles of induction chemotherapy was 83% (25/80). Therefore, the results met our criterion for feasibility.

      Conclusion
      Induction chemotherapy using a combination of cisplatin, pemetrexed and bevacizumab in patients with resectable clinical stage II/IIIA nonsquamous NSCLC is therefore considered to be a feasible treatment modality. Figure 1

  • +

    P3.07 - Poster Session 3 - Surgery (ID 193)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Surgery
    • Presentations: 1
    • +

      P3.07-031 - Surgical Outcome of Resected Lung Cancer Patients Complicated with Combined Pulmonary Fibrosis and Emphysema (ID 2348)

      09:30 - 09:30  |  Author(s): K. Suzuki

      • Abstract

      Background
      Combined pulmonary fibrosis and emphysema (CPFE) has been recently reported as a prognostic factor for patient with respiratory disorders. It might increase the risk of lung cancer. However controversisies remain as to surgical outcome in this population.

      Methods
      Retrospective study was performed on 981 patients who underwent surgical resection of lung cancer at our institute between 2008 and 2012. Findings on thin-section computed tomography which was available for all patients were reviewed. Based on the findings, patients complicated with CPFE were selected and clinicopathological features were investigated. Surgical outcome and prognosis following lung resection were also examined.

      Results
      CPFE was observed in 97 (9.1%) patients with resected lung cancer.　Patients with pulmonary fibrosis alone were 43 patients (43.8%), patients with emphysema alone were 148 patients (15.1%) and patients without abnormal shadow were 649 patients. Lung function test were as follows (CPFE/ Fibrosis/ Emphysema): vital capacity (VC); 3.3L/ 2.9L/ 3.5L, forced expiratory volume in one second (FEV1); 71.5%/ 77.4%/ 67.9%, diffuse capacity (DLco); 44.6%/ 58.1%/ 58.6%. Ninety day-mortality(CPFE/ Fibrosis/ Emphysema) was 10.2%/ 2.3%/ 1.1%. Risk factor of ninety day mortality in patients with CPFE was operative blood loss. CPFE patients also have higher risk of major complication after surgery (CPFE 44.3%, non-CPFE 8.1%). The statistically significant difference in survival was found with the Kaplan-Meier method (p<0.001). Survival at 2 years(CPFE/ Fibrosis/ Emphysema/ Normal) was 74.6%/ 88.2%/ 91.4%/ 93.6% and survival at 5 years (CPFE/ Fibrosis/ Emphysema/ Normal) was 58.6% /61.8% /72.9%/ 81.5%. Within CPFE patients, multivariable analysis of hazard ratio for prognosis showed following significant factors; pO2<70 (HR 13.52, p=0.001), lymph node metastasis (HR 10.89, p=0.002).

      Conclusion
      Surgery for patients with CPFE is feasible. Postoperative complications were frequently and prognosis is poor compared with either emphysema or fibrosis. Not only the status of lung cancer but also respiratory status is a risk factor of prognosis after surgery for primary lung cancer with CPFE.